Article thumbnail

High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma

By Wu ZL, Song YQ, Shi YF and J Zhu
Topics: Rapid Communication
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3163635
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). (Eds): World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues,
  2. (2009). A: Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI). J Hematol Oncol
  3. (2003). Ag e n e expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA
  4. (2008). BH: Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood
  5. (2004). Bromberg JF: Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA
  6. (2008). Cancer-related inflammation. Nature
  7. (2005). Connors JM: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
  8. (2007). Connors JM: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood
  9. (2010). Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica
  10. (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Rev Immunol
  11. (1994). Gatter KC: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood
  12. (2011). Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer. J Hematol Oncol
  13. (2009). H: IL-17 can promote tumor growth through an IL-6/Stat3 signaling pathway.
  14. (2008). H: Stat3 mediates myeloid cell dependent tumor angiogenesis in mice.
  15. (2008). Han ZC: STAT3: a critical transcription activator in angiogenesis. Med Res Rev
  16. (2002). Kenneth LWright: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene
  17. (2008). LM: Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-B pathways in subtypes of diffuse large B-cell lymphoma. Blood
  18. (2000). LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature
  19. (2002). Lymphoma/Leukemia Molecular Profiling Project: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
  20. (2005). Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nature Clin Pract Oncol
  21. (2011). R: STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma. Cancer Res
  22. (2000). Reddy EP: Janus kinases: components of multiple signaling pathways. Oncogene
  23. (2003). Russo A: STAT proteins: from normal control of cellular events to tumorigenesis.
  24. (2009). Shing Chien: ABT-869, a promising multi-targeted tyrosine kinase inhibitor:from bench to bedside. J Hematol Oncol
  25. (2004). STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets
  26. (2010). Thomas EWitzig: Targeted therapy of lymphoma.